Format:
1 Online-Ressource (73 Seiten)
,
21 x 29.7cm
Series Statement:
OECD Health Working Papers
Content:
This study analyses how 14 OECD Countries refer to "value" when making decisions on reimbursement and prices of new medicines. It details the type of outcomes considered, the perspective and methods adopted for economic evaluation when used; and the consideration of budget impact. It describes which dimensions are taken into account in the assessment of "innovativeness" and the consequences of this assessment on prices; it confirms that treatments for severe and/or rare diseases are often more valued than others and shows how countries use product-specific agreements in an attempt to better align value and price
Language:
English
DOI:
10.1787/5k43jc9v6knx-en
URL:
Volltext
(URL des Erstveröffentlichers)
